• Users Online: 147
  • Print this page
  • Email this page
Year : 2020  |  Volume : 4  |  Issue : 4  |  Page : 173-181

The future of injectable orthobiologic substances for knee osteoarthritis: Options beyond platelet-rich plasma

Department of Orthopaedics, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Dr. Karan Jindal
Post Graduate Institute of Medical Education and Research, Chandigarh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jmsr.jmsr_64_20

Rights and Permissions

The management of young arthritic knee and early grades of osteoarthritis (OA) aims to reduce morbidity and improve the quality of life for which newer modalities are emerging. Orthobiologics have emerged as a viable alternative option as they promote tissue regeneration and could be potential disease-modifying agents. Platelet-rich plasma (PRP) has been promising and is among the frontline treatment options in early OA knee; newer orthobiologic research is progressing beyond this and newer products are being tried. Various combinations of PRP with carriers and growth factor extracts from PRP are some new developments. Additional options beyond PRP include autologous conditioned serum, alpha-2 macroglobulin, adipose tissue derivative, bone marrow aspirate concentrate, and gene therapy. This review aims to shed light on the current literature and future potential of the use of these intra-articular orthobiologics in the 21st century.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded196    
    Comments [Add]    

Recommend this journal